- Arcutis buys UK’s Ducentis for up to $400M, as charity Lifearc celebrates first exit from venture arm BioWorld Online
- Arcutis Biotherapeutics agrees to acquire LifeArc portfolio company Ducentis BioTherapeut Seeking Alpha
- VC firm LifeArc sells first portfolio company as dermatitis-focused Ducentis bought by Arcutis for $30M FierceBiotech
- View Full coverage on Google News
Recent Comments